GENELUX Corp Price/Book Ratio
The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.
- GENELUX Corp price/book ratio for the quarter ending 2026-06-30 was 8.45, a 84.49% increase year-over-year.
- GENELUX Corp price/book ratio for the quarter ending 2026-03-31 was 4.71, a 38.12% increase year-over-year.
- GENELUX Corp price/book ratio for the quarter ending 2025-12-31 was 14.39, a 361.25% increase year-over-year.
- GENELUX Corp price/book ratio for the quarter ending 2025-09-30 was 8.62, a 248.30% increase year-over-year.
- GENELUX Corp price/book ratio for fiscal 2026 was 8.45.
- GENELUX Corp price/book ratio for fiscal 2025 was 14.39, a 361.25% increase from fiscal 2024.
- GENELUX Corp price/book ratio for fiscal 2024 was 3.12, a 83.82% decline from fiscal 2023.
- GENELUX Corp price/book ratio for fiscal 2023 was 19.27.
- Available history
- 2023-03-31 to 2026-06-30
- Data captured
Historical Price/Book Ratio
Annual Price/Book Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |